Zhu AX - Search Results

1

Ryoo BY, Merle P, Kulkarni AS, Cheng AL, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Daniele B, Norquist JM, Chen E, Siegel AB, Zhu AX, Finn RS, Kudo M. Ryoo BY, et al. Among authors: zhu ax. Cancer. 2021 Mar 15;127(6):865-874. doi: 10.1002/cncr.33317. Epub 2020 Nov 24. Cancer. 2021. PMID: 33231873 Free article. Clinical Trial.

2

Hepatocellular carcinoma: are we making progress?

Zhu AX. Zhu AX. Cancer Invest. 2003 Jun;21(3):418-28. doi: 10.1081/cnv-120018233. Cancer Invest. 2003. PMID: 12901288 Review.

3

Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?

Zhu AX. Zhu AX. Oncologist. 2006 Jul-Aug;11(7):790-800. doi: 10.1634/theoncologist.11-7-790. Oncologist. 2006. PMID: 16880238 Free article. Review.

4

Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.

Ryan DP, Appleman LJ, Lynch T, Supko JG, Fidias P, Clark JW, Fishman M, Zhu AX, Enzinger PC, Kashala O, Cusack J Jr, Eder JP. Ryan DP, et al. Among authors: zhu ax. Cancer. 2006 Nov 15;107(10):2482-9. doi: 10.1002/cncr.22264. Cancer. 2006. PMID: 17036355 Free article. Clinical Trial.

5

Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma.

Zhu AX, Stuart K, Blaszkowsky LS, Muzikansky A, Reitberg DP, Clark JW, Enzinger PC, Bhargava P, Meyerhardt JA, Horgan K, Fuchs CS, Ryan DP. Zhu AX, et al. Cancer. 2007 Aug 1;110(3):581-9. doi: 10.1002/cncr.22829. Cancer. 2007. PMID: 17583545 Free article. Clinical Trial.

6

Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma.

Zhu AX. Zhu AX. Cancer. 2008 Jan 15;112(2):250-9. doi: 10.1002/cncr.23175. Cancer. 2008. PMID: 18041064 Free article.

7

Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma.

Zhu AX, Holalkere NS, Muzikansky A, Horgan K, Sahani DV. Zhu AX, et al. Oncologist. 2008 Feb;13(2):120-5. doi: 10.1634/theoncologist.2007-0174. Oncologist. 2008. PMID: 18305056 Free article. Clinical Trial.

8

Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells.

Fuchs BC, Fujii T, Dorfman JD, Goodwin JM, Zhu AX, Lanuti M, Tanabe KK. Fuchs BC, et al. Among authors: zhu ax. Cancer Res. 2008 Apr 1;68(7):2391-9. doi: 10.1158/0008-5472.CAN-07-2460. Cancer Res. 2008. PMID: 18381447

9

Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab.

Finn RS, Zhu AX. Finn RS, et al. Among authors: zhu ax. Expert Rev Anticancer Ther. 2009 Apr;9(4):503-9. doi: 10.1586/era.09.6. Expert Rev Anticancer Ther. 2009. PMID: 19374603 Review.

10

Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma.

Vora SR, Zheng H, Stadler ZK, Fuchs CS, Zhu AX. Vora SR, et al. Among authors: zhu ax. Oncologist. 2009 Jul;14(7):717-25. doi: 10.1634/theoncologist.2009-0038. Epub 2009 Jul 6. Oncologist. 2009. PMID: 19581525 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

397 results

Search Page

Filters